Back to Sites

Seke North CRS

Site Number

30306

Address

Seke North CRS
15 Phillips Avenue
Belgravia
Harare,
Zimbabwe

IMPAACT Members at this Site

Lynda Stranix-Chibanda Clinical/Site Coordinator

Patricia Mandima CRS Coordinator

Suzen Maonera CRS Coordinator

Teacler Nematadzira CRS Coordinator

Gift Chareka CTU Coordinator

Zvavahera Chirenje CTU Principal Investigator

Bola Adedeji DAIDS PO

Daylight Sanyanga Ngwazi Investigator

Marshall Munjoma Laboratory Manager/Supervisor

Bangani Kusakara Medical Officer

Vongai Chanaiwa Pharmacist

Caroline Govathson Pharmacist of Record

Studies at this Site

P1078: TB APPRISE: TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed infants

DAIDS Number

10732

Research Area

Tuberculosis

Study Status

Participants Off Study and Primary Analysis Completed

P1084s: Maternal Infant TDF Toxicity Safety

DAIDS Number

10790

Research Area

Therapeutics

Study Status

Closed to Follow Up

1077BF: PROMISE 1077BF

DAIDS Number

10777

Research Area

Prevention

Study Status

Participants Off Study and Primary Analysis Completed

P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study

DAIDS Number

11954

Research Area

Cure and Immunotherapy

Study Status

Enrolling

IMPAACT 2009 : Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants

DAIDS Number

30020

Research Area

Therapeutics

Study Status

Closed to Follow Up

IMPAACT 2010: VESTED

DAIDS Number

30129

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings

DAIDS Number

38506

Research Area

Brain and Mental Health

Study Status

Enrolling

IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

DAIDS Number

38609

Research Area

Therapeutics

Study Status

Enrolling

IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Two to Less Than 13 Years of Age with and without HIV

DAIDS Number

38747

Research Area

Tuberculosis

Study Status

In Development

IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV

DAIDS Number

38693

Research Area

Cure and Immunotherapy

Study Status

Enrolling